Showing results (161-170 of 190) with videos related to
Sort By:
Pageof 19
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but AlsoJohn M S Bartlett, Christopher C McConkey, Alison F Munro, et al.Nature|December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy responseStephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.Pageof 19